Related references
Note: Only part of the references are listed.Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
Bruce D. Cheson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
Toshihiko Doi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Martin Dreyling et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Georg Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
Juliane Paul et al.
CANCER CELL (2017)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
Follicular lymphoma: evolving therapeutic strategies
Brad S. Kahl et al.
BLOOD (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
CHRONOS-2: A randomized, double-blind phase III study of phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL)
Grzegorz S. Nowakowski et al.
CANCER RESEARCH (2015)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2011)
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel et al.
BLOOD (2011)